Pharmacological Activation of Brown Adipose Tissue Metabolism

Type 2 Diabetes Clinical Trial

— GB6  

Official title:

Pharmacological or Cold-induced Activation of Brown Adipose Tissue Metabolism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02811289
• Other study ID #: 2016-1086
• Status: Completed
• Phase: N/A
• Start date: August 5, 2016
• Est. completion date: July 5, 2018

Study information

• Verified date: August 2018
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lean tissue intracellular triglycerides (ICTG) accretion is an important marker of lean tissue lipotoxicity that significantly contributes to the development of type 2 diabetes (T2D). The mechanisms leading to excess exposure of lean tissues to fatty acids involve metabolic dysfunctions of adipose tissues and lean tissues themselves. Understanding the role of white and brown adipose tissue in this metabolic dysfunction is particularly important in predicting, preventing and treating T2D and many of its associated cardiovascular complications.

A recent breakthrough has been the demonstration that the acute oral administration of a β3 adrenergic agonist, mirabegron (200 mg), significantly increases BAT glucose uptake in healthy individuals. This suggests that mirabegron could be used as a pharmacological tool to selectively activate BAT metabolism as part of the mechanistic studies on BAT. It also suggests that mirabegron could be used pharmacologically for chronic activation of BAT in clinical trials to treat obesity and T2D. However, there are some outstanding issues regarding the use of mirabegron to activate BAT. First, there has been no direct comparison of the effect of acute cold vs. mirabegron on BAT metabolism. Second, there has been no demonstration of the effect of mirabegron on BAT oxidative metabolism since glucose uptake is only a surrogate of BAT energy expenditure. Third, acute administration of mirabegron led to significant increases in blood pressure and cardiac work, suggesting that it may also enhance energy expenditure in other organs in addition to BAT, thus confounding the role of BAT in energy homeostasis. Therefore, much remains to be known about the effect of mirabegron on BAT and cardiac energy metabolism before this drug can be used as a selective activator of BAT oxidative metabolism. The purpose of this study is to directly compare BAT oxidative metabolism under cold vs. β3-adrenergic agonist stimulation in lean healthy individuals. The investigator hypothesizes that the acute oral administration of a lower dose of mirabegron (50 mg) will result in an increase in BAT oxidative metabolism and whole-body energy expenditure, to a similar extent as cold exposure, without influencing the cardiovascular responses previously seen with the higher dose (200 mg).

Description:

The first step of the study will be direct comparison of mirabegron (protocol A) vs. cold-induced (protocol B) BAT metabolic activation using 11C-acetate to measure BAT metabolic activity. The principle of this method is measurement of tissue fast disappearance of 11C, a marker of tissue 11CO2 production. This fast tissue 11C clearance thus gives an index of tissue oxidative metabolism. Ten healthy, non obese men will undergo two identical 5h procedures in which BAT metabolism will be stimulated with a β3-agonist (mirabegron 50mg) or using cold exposure, in random order. The investigator just received approval from Health Canada to use mirabegron as part of these metabolic investigations. In brief, baseline blood samples and indirect calorimetry will be performed between time -60 to -30 min followed by i.v. injection of 11C-acetate with 30 min dynamic PET/CT scanning at room temperature in both protocol A and B. Mirabegron will be administered orally at time 0 in protocol A whereas acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B. At time 210 min (i.e. Tmax of plasma mirabegron level or 90 min after the onset of cold exposure), i.v. injection of 11C-acetate will be repeated followed by 30 min dynamic PET/CT scanning. I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning to determine BAT net glucose uptake and a whole-body PET/CT scan to determine BAT volume of metabolic activity and organ-specific glucose partitioning.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: July 5, 2018
• Est. primary completion date: May 24, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• BMI < 30 kg/m2

• normal glucose tolerance (2-hour post 75g OGTT glucose at < 7.8 mmol/l

• HbA1c < 5.8%

Exclusion Criteria:

• overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG;

• treatment with any drug known to affect lipid or carbohydrate metabolism;

• presence of liver or renal disease, uncontrolled thyroid disorder, previous pancreatitis, bleeding disorder, or other major illness;

• smoking (>1 cigarette/day) and/or consumption of >2 alcoholic beverages per day;

• prior history or current fasting plasma cholesterol level > 7 mmol/l or fasting TG > 6 mmol/l.

Related Conditions & MeSH terms

• Type 2 Diabetes

Intervention

Drug:
• Mirbetriq (Mirabegron)
50mg of Mirabegron will be administered orally at time 0 in protocol A.

Other:
• cold exposure
Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B

Radiation:
• injection of 18FDG
I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
• injection of 11C-acetate
i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
• [3-3H]-glucose
i.v. administration of 1.5 uCi/min of [3-3H]-glucose

Other:
• [U-13C]-palmitate
i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
• 2H-Glycerol
i.v. administration of 0.05 µmol/kg/min of 2H-glycerol

Locations

Country	Name	City	State
Canada	centre de recherche du CHUS	Sherbrooke	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BAT net glucose uptake	will be assessed using i.v. injection of 18FDG with sequential dynamic PET/CT scanning.	2 years
Primary	BAT oxidative metabolism	will be determined using i.v. injection of 11C-acetate during dynamic PET/CT scanning	2 years
Primary	BAT volume of metabolic activity	will be determined using a total body CT (16 mA) followed by a PET acquisition.	2 years
Primary	whole body organ glucose partitioning	will be determined using a total body CT (16 mA) followed by a PET acquisition be determined using a total body CT (16 mA) followed by a PET acquisition	2 years
Secondary	lipolysis rate	will be measured using i.v. administration of [13C]-palmitate and [2H]-glycerol, using steele's non steady state equations	2 years
Secondary	Glucose appearance rate	will be determined using [3-3H]-glucose	2 years
Secondary	Energy expenditure	will be determined by indirect calorimetry from VO2 and VCO2 (Vmax29n, Sensormedics)	2 years
Secondary	Insulin sensitivity	will be determined using the HOMA-IR (based on fasting insulin and glucose levels)	2 years
Secondary	Insulin secretion rate	will be assessed using deconvolution of plasma C-peptide with standard C-peptide kinetic parameters	2 years
Secondary	ß-cell function	will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin sensitivity.	2 years
Secondary	metabolite responses	will be determined using a multiplex assay system	2 years
Secondary	Electrocardiogram		2 years